Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by USFDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic MyelomonocyticLeukemia (CMML)

By
Noshin Noorjahan
-
0
35
Immune-Onc Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).
[Immune-Onc Therapeutics, Inc.]
Press Release